Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial

Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no evidence‐proven treatment beyond the second line in patients with SCLC and liver metastasis. This study aimed to investigate survival in patients with SCLC and liver metastasis treated with anlotinib compared with plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Wang, Qiming, Li, Kai, Shi, Jianhua, Wu, Lin, Han, Baohui, Chen, Gongyan, He, Jianxing, Wang, Jie, Qin, Haifeng, Li, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855912/
https://www.ncbi.nlm.nih.gov/pubmed/34939373
http://dx.doi.org/10.1002/cam4.4507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855912/
https://www.ncbi.nlm.nih.gov/pubmed/34939373
http://dx.doi.org/10.1002/cam4.4507

Ejemplares similares